91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

跳到内容

语言

切换导航

我的购物车

搜索

菜单

账号

设置

语言

Tremelimumab (anti-CTLA-4)

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

纯度: ＞95% (SDS-PAGE&SEC)
应用: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab169301-1mg	1mg	现货
Ab169301-5mg	5mg	现货
Ab169301-10mg	10mg	期货

查看相关系列

cytotoxic T-lymphocyte-associated protein 4 (CD152) Antibody

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本描述

产品名称	Tremelimumab (anti-CTLA-4)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
产品介绍	Tremelimumab 是一种anti-CTLA-4单克隆抗体，对细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 具有特异性，可用于转移性黑色素瘤研究。 Tremelimumab is an anti-CTLA-4 monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
偶联标记	Unconjugated
Accession#	P16410
来源	CHO supernatant
SDS-PAGE	26.1 kDa (Light Chain) & 52.2 kDa (Heavy Chain), under reducing conditions; 178.0 kDa, under non-reducing conditions.

产品规格参数

应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	745013-59-6

数据库链接

IMGT/mAb-DB	248
Wikipedia	Tremelimumab

靶标

Target ID

2743

名称

cytotoxic T-lymphocyte-associated protein 4 (CD152)

缩写名

CTLA-4

家族

Other immune checkpoint proteins

别名

KCa2.1

基因和蛋白信息

Species	Transmembrane Domains	Amino Acids	Chromosomal Location	Gene Symbol	Gene Name
Human	1	223	2q33.2	CTLA4	cytotoxic T-lymphocyte associated protein 4
Mouse	1	223	1 30.58 cM	Ctla4	cytotoxic T-lymphocyte-associated protein 4
Rat	2	223	9q31	Ctla4	cytotoxic T-lymphocyte-associated protein 4

RefSeq Protein

NP_005205 (Hs) , NP_033973 (Mm) , NP_113862 (Rn)

RefSeq Nucleotide

NM_005214 (Hs) , NM_009843 (Mm) , NM_031674 (Rn)

Entrez Gene

1493 (Hs) , 12477 (Mm) , 63835 (Rn)

UniProtKB

P09793 (Mm) , P16410 (Hs)

Ensembl Gene

ENSG00000163599 (Hs) , ENSMUSG00000026011 (Mm) , ENSRNOG00000054129 (Rn)

OMIM

123890 (Hs)

Protein GI

21361212 (Hs) , 31981847 (Mm) , 13928934 (Rn)

DrugBank Target

P16410 (Hs)

CATH/Gene3D

2.60.40.10 (N/A)

ChEMBL Target

CHEMBL2364164 (Hs)

关联配体

Ligand ID	8462
名称	tremelimumab
别名	CP-675
类别	Antibody
学名	4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价	Data for two antibody clones measured by competition ELISAs are provided in US 6682736 . Clones 4.1.1. and 11.2.1 inhibit binding of CD80 and CD86 to CTLA4 with almost identical IC₅₀ values. The affinity for direct binding between antibody and CTLA4 is only provided for subclone 4.1.1.1 in this patent.
评价	Tremelimumab is a fully human investigational monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152). Tremelimumab was designed as an antineoplastic agent. A BLAST sequence alignment matches tremelimumab to patent US 6682736, and identifies antibody clone 11.2.1 .
配体家族	Immune checkpoint modulators
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰

参考文献

1. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. (2006) Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.. Cancer, 106 (11): (2437-44). [PMID:16615096]
2. Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M et al.. (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.. Lancet Respir Med, 3 (4): (301-9). [PMID:25819643]
3. Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. (2015) A phase 2 study of tremelimumab in patients with advanced uveal melanoma.. Melanoma Res, 25 (4): (342-7). [PMID:26050146]